Sequential Combination Therapy With PD-1 Antibody and Peg-IFNα in CHB Patients

NCT06457477 · clinicaltrials.gov ↗

NA

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: Sintilimab
DRUG: NAs
DRUG: Peg-IFNα-2b

Sponsor

Beijing 302 Hospital